File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.tube.2018.07.003
- Scopus: eid_2-s2.0-85053841943
- PMID: 30514515
- WOS: WOS:000451766300009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: In vivo electroporation of a codon-optimized BERopt DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge
Title | In vivo electroporation of a codon-optimized BERopt DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge |
---|---|
Authors | |
Keywords | Tuberculosis DNA vaccine BERopt BCG Mycobacterium tuberculosis |
Issue Date | 2018 |
Publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/tube |
Citation | Tuberculosis, 2018, v. 113, p. 65-75 How to Cite? |
Abstract | DNA vaccines have been extensively studied as preventative and therapeutic interventions for various infectious diseases such as tuberculosis, HIV/AIDS and influenza. Despite promising progresses made, improving the immunogenicity of DNA vaccine remains a technical challenge for clinical development. In this study, we investigated a tuberculosis DNA vaccine BERopt, which contained a codon-optimized fusion immunogen Ag85B-ESAT-6-Rv2660c for enhanced mammalian cell expression and immunogenicity. BERopt immunization through in vivo electroporation in BALB/c mice induced surprisingly high frequencies of Ag85B tetramer(+) CD8(+) T cells in peripheral blood and IFN-gamma-secreting CD8(+) T cells in splenocytes. Meanwhile, the BERopt vaccine-induced long-lasting T cell immunity protected BALB/c mice from high dose viral challenge using a modified vaccinia virus Tiantan strain expressing mature Ag85B protein (MVTT-m85B) and the virulent M. tb H37Rv aerosol challenge. Since the BERopt DNA vaccine does not induce anti-vector immunity, the strong immunogenicity and protective efficacy of this novel DNA vaccine warrant its future development for M. tb prevention and immunotherapy to alleviate the global TB burden. |
Persistent Identifier | http://hdl.handle.net/10722/274421 |
ISSN | 2023 Impact Factor: 2.8 2023 SCImago Journal Rankings: 0.605 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tang, J | - |
dc.contributor.author | Cai, Y | - |
dc.contributor.author | Liang, J | - |
dc.contributor.author | Tan, Z | - |
dc.contributor.author | Tang, X | - |
dc.contributor.author | Zhang, C | - |
dc.contributor.author | Cheng, L | - |
dc.contributor.author | Zhou, J | - |
dc.contributor.author | Wang, H | - |
dc.contributor.author | Yam, WC | - |
dc.contributor.author | Chen, X | - |
dc.contributor.author | Wang, H | - |
dc.contributor.author | Chen, Z | - |
dc.date.accessioned | 2019-08-18T15:01:24Z | - |
dc.date.available | 2019-08-18T15:01:24Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Tuberculosis, 2018, v. 113, p. 65-75 | - |
dc.identifier.issn | 1472-9792 | - |
dc.identifier.uri | http://hdl.handle.net/10722/274421 | - |
dc.description.abstract | DNA vaccines have been extensively studied as preventative and therapeutic interventions for various infectious diseases such as tuberculosis, HIV/AIDS and influenza. Despite promising progresses made, improving the immunogenicity of DNA vaccine remains a technical challenge for clinical development. In this study, we investigated a tuberculosis DNA vaccine BERopt, which contained a codon-optimized fusion immunogen Ag85B-ESAT-6-Rv2660c for enhanced mammalian cell expression and immunogenicity. BERopt immunization through in vivo electroporation in BALB/c mice induced surprisingly high frequencies of Ag85B tetramer(+) CD8(+) T cells in peripheral blood and IFN-gamma-secreting CD8(+) T cells in splenocytes. Meanwhile, the BERopt vaccine-induced long-lasting T cell immunity protected BALB/c mice from high dose viral challenge using a modified vaccinia virus Tiantan strain expressing mature Ag85B protein (MVTT-m85B) and the virulent M. tb H37Rv aerosol challenge. Since the BERopt DNA vaccine does not induce anti-vector immunity, the strong immunogenicity and protective efficacy of this novel DNA vaccine warrant its future development for M. tb prevention and immunotherapy to alleviate the global TB burden. | - |
dc.language | eng | - |
dc.publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/tube | - |
dc.relation.ispartof | Tuberculosis | - |
dc.subject | Tuberculosis | - |
dc.subject | DNA vaccine | - |
dc.subject | BERopt | - |
dc.subject | BCG | - |
dc.subject | Mycobacterium tuberculosis | - |
dc.title | In vivo electroporation of a codon-optimized BERopt DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge | - |
dc.type | Article | - |
dc.identifier.email | Tan, Z: zwtan@hku.hk | - |
dc.identifier.email | Yam, WC: wcyam@hkucc.hku.hk | - |
dc.identifier.email | Chen, Z: zchenai@hku.hk | - |
dc.identifier.authority | Yam, WC=rp00313 | - |
dc.identifier.authority | Chen, Z=rp00243 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.tube.2018.07.003 | - |
dc.identifier.pmid | 30514515 | - |
dc.identifier.scopus | eid_2-s2.0-85053841943 | - |
dc.identifier.hkuros | 301454 | - |
dc.identifier.volume | 113 | - |
dc.identifier.spage | 65 | - |
dc.identifier.epage | 75 | - |
dc.identifier.isi | WOS:000451766300009 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1472-9792 | - |